Published in Healthcare Mergers, Acquisitions and Ventures Week, April 17th, 2004
In the comparable quarter of fiscal 2003, Accelr8, whose fiscal year ends July 31, reported a net loss of $281,000, or $0.03 per share, on net revenues of $202,000.
"During the quarter," said Thomas Geimer, Accelr8's chairman and chief executive officer, "we advanced our development of BACcelr8r, an analytical system that will integrate our three existing technologies - OptiChem, QuanDx, and YoDx - into a platform of measurement instruments and disposable analytical test chips for use in medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.